Adjuvanted seasonal recombinant QVLP influenza vaccine - Medicago
Latest Information Update: 02 Aug 2023
At a glance
- Originator Medicago
- Class Influenza virus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 26 Apr 2022 Medicago completes phase-I/II trial in Influenza virus infections (Prevention, In the elderly) in USA (IM, Injection) (NCT04622592)
- 02 Nov 2020 Phase-I/II clinical trials in Influenza virus infections (Prevention, In the elderly) in USA (IM, Injection) (NCT04622592)
- 28 Oct 2020 Preclinical trials in Influenza virus infections in USA (IM, Injection), prior to October 2020